Myeloma Clinical Trial
Official title:
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
Study aiming at testing the positive predictive value of the Hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry
Multiple Myeloma is a pathology for which treatments are constantly progressing. These
treatments allow more and more patients to reach deeper and deeper responses. Currently, it
is possible to detect very low levels of disease : this is called the evaluation of minimal
residual disease. Its prognostic value is strong.
Two techniques currently prevail in the evaluation of minimal residual disease: high
throughput sequencing (NGS) and multi-parameter flow cytometry. They are included in
evaluation criteria defined by the International Myeloma Working Group (IMWG). These
techniques have the advantage of being very sensitive, reaching 10-5 (cytometry: 50 events
among 5 000 000 cells analysed) to 10-6 (NGS). Nevertheless, they are invasive for the
patient (medullary specimen), require technical expertise and are not necessarily available
in all hospitals.
The development of blood tests would cope with this constraints.
The Hevylite® assay is a simple, sensitive, automated and inexpensive immunologic technique
that allows the accurate quantification of total IgG, Total IgG, Total IgA, Total IgA L,
Total IgM, and Total IgM in the blood. Given its characteristics, the Hevylite assay could
play a role in the definition of MRD and allow evaluation of residual disease in myeloma.
This study aims to evaluate the positive predictive value of the Hevylite test in the
evaluation of residual disease in myeloma in comparison with multiparametric flow cytometry
on the bone marrow.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03832127 -
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
|
Phase 1 | |
| Completed |
NCT01413178 -
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
|
Phase 3 | |
| Recruiting |
NCT03641456 -
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT03135925 -
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
|
N/A | |
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02114502 -
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
|
Phase 2 | |
| Completed |
NCT00794261 -
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
|
Phase 2 | |
| Completed |
NCT01700608 -
Prospective Observational Study on Plerixafor After Chemotherapy
|
N/A | |
| Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Recruiting |
NCT05528887 -
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05625971 -
Non-invasive MRD Assessment in Multiple Myeloma
|
||
| Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
| Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT02542657 -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01191060 -
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
|
Phase 3 | |
| Completed |
NCT01279694 -
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00983346 -
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
|
Phase 2 | |
| Completed |
NCT00476294 -
Long-Term Follow Up Study for AMD3100 Patients
|
N/A |